{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:38:38Z","timestamp":1791412718909,"version":"4.3.3"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semnuclmed.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T20:37:28Z","timestamp":1668199048000},"page":"371-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Interim FDG-PET\/CT for Response Assessment of Lymphoma"],"prefix":"10.1053","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-480X","authenticated-orcid":false,"given":"Merissa N.","family":"Zeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma A.","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-078X","authenticated-orcid":false,"given":"Heather A.","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0001","first-page":"19S","article-title":"Integrating PET and PET\/CT into the risk-adapted therapy of lymphoma","volume":"48","author":"Kasamon","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0002","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CCO.0b013e3282f5123d","article-title":"FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma","volume":"20","author":"Kasamon","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0003","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00259-014-2973-6","article-title":"FDG PET\/CT imaging as a biomarker in lymphoma","volume":"42","author":"Meignan","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0004","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0005","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.2967\/jnumed.108.057190","article-title":"PET\/CT for therapy response assessment in lymphoma","volume":"50","author":"Hutchings","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0006","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0007","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","article-title":"FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma","volume":"16","author":"Mikhaeel","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0008","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: A comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0009","article-title":"Risk assessment in diffuse large B-cell lymphoma by combining baseline metabolic tumor volume and Peking criteria when evaluating series 18F-fluorodeoxyglucose positron emission tomography scans","volume":"12","author":"Yuan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0010","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0012","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0013","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: Comparison between Deauville criteria and SUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0014","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0015","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0016","first-page":"4020","article-title":"Metabolic tumor volume for early response assessment in early-stage unfavorable Hodgkin lymphoma treated with Nivolumab in the GHSG Nivahl Phase II trial","volume":"134","author":"Voltin","year":"2019","journal-title":"Bood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0017","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0018","series-title":"World Health Organization classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0019","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Hodgkin Lymphoma (Version 1.2023). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf, Accessed September 4, 2022"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0020","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: A systematic review and meta-analysis of prognostic factor studies","volume":"9","author":"Aldin","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0021","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","author":"Hutchings","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0022","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0023","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0024","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1007\/s00259-011-1741-0","article-title":"Prognostic value of interim FDG PET\/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: Comparison of International Harmonization Project (IHP), Gallamini and London criteria","volume":"38","author":"Le Roux","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0025","unstructured":"Surveillance, Epidemiology, and End Results (SEER) 18 registries, National Cancer Institute, 2021. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html. Accessd on September 1, 2022."},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0609.2005.00450.x","article-title":"Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG)","volume":"66","author":"Behringer","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0027","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0028","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0029","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0030","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: Risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0031","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0032","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): A multicentre, open-label, randomized, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0033","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0034","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0035","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0036","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated beacopp in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: Long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0037","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0038","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0039","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0040","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron Emission Tomography-driven strategy in advanced Hodgkin lymphoma: Prolonged follow-up of the AHL2011 phase III lymphoma study association study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0041","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0042","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): Follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissel","year":"2021","journal-title":"The Lancet Haematology"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2022.10.004_bib0043","first-page":"23","article-title":"SWOG S1826: a phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0044","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0045","unstructured":"National Comprehensive Cancer Network clinical practice guidelines in oncology B-cell lymphomas (Version 5.2022) Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed September 4, 2022"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0046","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/annonc\/mdn629","article-title":"High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens","volume":"20","author":"Han","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0047","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41408-022-00649-x","article-title":"PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: Results of two independent prospective cohorts","volume":"12","author":"Desai","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0048","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Mamot","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0049","first-page":"2224","article-title":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: Results from the CALGB 50303","volume":"135","author":"Sch\u00f6der","year":"2020","journal-title":"Clin Trial Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","article-title":"Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: A systematic review and meta-analysis","volume":"46","author":"Burggraaff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0051","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2967\/jnumed.120.244145","article-title":"Interim PET evaluation in diffuse large B-cell lymphoma using published recommendations: Comparison of the Deauville 5-point scale and the \u0394SUVmax method","volume":"62","author":"Rekowski","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0052","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2967\/jnumed.121.262205","article-title":"18F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: The HOVON-84 study","volume":"63","author":"Burggraaff","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0053","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2021-151362","article-title":"Circulating tumor DNA integrated with interim [18F]FDG PET Is highly effective in predicting outcome of relapsed\/refractory classical Hodgkin lymphoma treated with the Begev regimen","volume":"138","author":"Di Trani","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0054","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00259-021-05498-7","article-title":"Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements","volume":"49","author":"Eertink","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. [published correction appears in Eur J Cancer 136:207-208, 2020]","volume":"124","author":"Schmitz","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0056","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00259-018-4198-6","article-title":"Prognostic analysis of interim 18F-FDG PET\/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy","volume":"46","author":"Yuan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0057","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0058","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0059","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0061","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cam4.2404","article-title":"Interim PET\/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109301","article-title":"Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET\/CT","volume":"133","author":"Li","year":"2020","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0063","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: The phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0064","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): Secondary analysis of a randomised, phase 3 trial [published correction appears in Lancet Oncol. 2019 Apr 29]","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0065","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10428190701422059","article-title":"Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma","volume":"48","author":"Bishu","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0066","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.2147\/CMAR.S216445","article-title":"Prognostic values of baseline, interim and end-of therapy 18F-FDG PET\/CT in patients with follicular lymphoma","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0067","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [18F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0068","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12149-014-0874-1","article-title":"The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma","volume":"28","author":"Lu","year":"2014","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0069","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12935-021-02094-5","article-title":"Significance of initial, interim and end-of-therapy 18F-FDG PET\/CT for predicting transformation risk in follicular lymphoma","volume":"21","author":"Xie","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0070","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis","volume":"85","author":"Adams","year":"2016","journal-title":"Eur J Radiol"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2022.10.004_bib0071","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-135919","article-title":"Interim Positron Emission Tomography (iPET) assessed using deauville score for patients with follicular lymphoma receiving first-line chemoimmunotherapy","volume":"136","author":"Merryman","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0072","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients","volume":"59","author":"Cottereau","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0073","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","article-title":"Prognostic significance of interim PET\/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma","volume":"15","author":"Jung","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0074","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0075","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/10428194.2016.1236380","article-title":"Value of interim FDG PET\/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma","volume":"58","author":"Moon","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0076","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1634\/theoncologist.2013-0463","article-title":"Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma","volume":"19","author":"Pellegrini","year":"2014","journal-title":"Oncologist"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0077","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12880-021-00674-5","article-title":"The role of pre-treatment and mid-treatment 18F-FDG PET\/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Med Imaging"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0078","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hon.2697","article-title":"Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial","volume":"38","author":"Schmitz","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0079","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1002\/cam4.3226","article-title":"Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma","volume":"9","author":"Kitadate","year":"2020","journal-title":"Cancer Med"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/annonc\/mdq415","article-title":"18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T\/NK lymphomas: a study from the GOELAMS group","volume":"22","author":"Cahu","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0081","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: A review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0082","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-021-00827-1","article-title":"Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma","volume":"11","author":"Kurch","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0083","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/10428194.2018.1482541","article-title":"Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET\/CT in adult Burkitt's lymphoma: The role of Deauville and IHP criteria","volume":"60","author":"Albano","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0084","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00277-014-2043-y","article-title":"The impact of R-VACOP-B and interim FDG-PET\/CT on outcome in primary mediastinal large B cell lymphoma","volume":"93","author":"Avigdor","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0085","first-page":"420","article-title":"Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01\u2013142) without radiotherapy for patients with primary mediastinal large B cell lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood ASH Annu Meet Abstr"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0086","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1038\/s41598-020-68310-w","article-title":"Prognostic significance of interim PET\/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era","volume":"10","author":"Song","year":"2020","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0087","article-title":"Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET\/CT parameters in extranodal natural killer\/T-cell lymphoma: A meta-analysis","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.10.004_bib0088","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1186\/s40880-015-0057-z","article-title":"Prognostic values of interim and post-therapy 18F-FDG PET\/CT scanning in adult patients with Burkitt's lymphoma","volume":"34","author":"Wei","year":"2015","journal-title":"Chin J Cancer"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:41:36Z","timestamp":1757544096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0001299822000927"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.004","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interim FDG-PET\/CT for Response Assessment of Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}